NASDAQ
BridgeBio Pharma, Inc. (BBIO) has a free cash flow growth of -223.77% as of Friday, May 29, 2026. This represents a 1335.20% decrease compared to its 12-month average of 18.12%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.